2nd Quarter - Report

THE DUBERSTEIN GROUP INC. for PFIZER INC.

Firm
Client
Income
$100,000
Expenses
—

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

TransPacific Partnership negotiations - Executive Branch action re this issue.

LobbyistCovered position, as disclosed
MICHAEL BERMAN —
STEVEN CHAMPLIN —
KENNETH DUBERSTEIN —
BRIAN GRIFFIN —
DANIEL P MEYER —
MARTI THOMAS —
ERIC UELAND —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Natl Institutes of Health (NIH)

Medicare/Medicaid MMM

Medicare Part D rebates - Proposed legislation re this issue.

LobbyistCovered position, as disclosed
MICHAEL BERMAN —
STEVEN CHAMPLIN —
KENNETH DUBERSTEIN —
BRIAN GRIFFIN —
DANIEL P MEYER —
MARTI THOMAS —
ERIC UELAND —

Contacted: Natl Institutes of Health (NIH); SENATE; HOUSE OF REPRESENTATIVES

Defense DEF

Homeland Security and Defense issues surrounding readiness for a chemical nerve agent attack or industrial accident - Proposed legislation re this issue; Executive Branch actions re this issue.

LobbyistCovered position, as disclosed
MICHAEL BERMAN —
STEVEN CHAMPLIN —
KENNETH DUBERSTEIN —
BRIAN GRIFFIN —
DANIEL P MEYER —
MARTI THOMAS —
ERIC UELAND —

Contacted: Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Corporate tax reform, including international taxes, tax extenders, repatriation, and patent box - Proposed legislation re these issues. *Foreign-controlled corporations look-through permanency - HR 2735, To amend the Internal Revenue Code of 1986 to make permanent the look-through treatment of payments between related controlled foreign corporations. *Excess returns - HR 2495, Tax Equity and Middle Class Fairness Act of 2011. *Offshoring - HR 2280, Offshoring Prevention Act; S 45, Offshoring Prevention Act. *Reinvestment of foreign earnings - S 1671, Foreign Earnings Reinvestment Act. *Tax havens - S 1346, Stop Tax Haven Abuse Act.

LobbyistCovered position, as disclosed
MICHAEL BERMAN —
STEVEN CHAMPLIN —
KENNETH DUBERSTEIN —
BRIAN GRIFFIN —
DANIEL P MEYER —
ERIC UELAND —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH)

Bills named: H.R. 2280 (112th), H.R. 2735 (112th), H.R. 2495 (112th)

Health Issues HCR

Implementation of the Patient Protection and Affordable Care Act, including Supreme Court case and coverage issues - Proposed legislation re these issues; Executive Branch actions re these issues. Congressional investigation regarding the Patient Protection and Affordable Care Act. *FDA funding - HR 5973, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013; S 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. *Antimicrobial resistence. *Repeal Independent Payment Advisory Board provision of PL 111-148, PL 111-152 - HR 452, Medicare Decisions Accountability Act of 2011; S 668, Health Care Bureaucrats Elimination Act.

LobbyistCovered position, as disclosed
MICHAEL BERMAN —
STEVEN CHAMPLIN —
KENNETH DUBERSTEIN —
BRIAN GRIFFIN —
DANIEL P MEYER —
MARTI THOMAS —
ERIC UELAND —

Contacted: Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 5973 (112th), H.R. 452 (112th)

Pharmacy PHA

Drug shortages - Proposed legislation re these issues. Opiate abuse - HR 1316, Stop Oxy Abuse Act of 2011; HR 2119, Ryan Creedon Act of 2011; HR 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011; HR 1065, Pill Mill Crackdown Act of 2011; S 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; Executive Branch action re this issue. Pharmaceutical issues, including tracking and tracing medicines, fostering competition between generic and brand-name pharmaceutical manufacturers - HR 5651, Food and Drug Administration Reform Act of 2012; S 3187, Food and Drug Administration Safety and Innovation Act. Incentives to develop antibiotics - HR 2182, Generating Antibiotic Incentives Now Act of 2011; S 1734, Generating Antibiotic Incentives Now Act of 2011. Establish criminal penalties for trafficking in counterfeit drugs - HR 3468, Counterfeit Drug Penalty Enhancement Act of 2011; S 1886, Counterfeit Drug Penalty Enhancement Act of 2011. National Center for Advancing Transformational Sciences at FDA; agreement to review compounds for potential new uses - Executive Branch actions re these issues. *Follow-on biologics generally. *Certified Importer Program. *Drug safety - HR 1483, Drug Safety Enhancement Act of 2011.

LobbyistCovered position, as disclosed
MICHAEL BERMAN —
STEVEN CHAMPLIN —
KENNETH DUBERSTEIN —
BRIAN GRIFFIN —
DANIEL P MEYER —
MARTI THOMAS —
ERIC UELAND —

Contacted: SENATE; Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES

Bills named: H.R. 2182 (112th), H.R. 2119 (112th), H.R. 1316 (112th), H.R. 5651 (112th), H.R. 866 (112th), H.R. 1065 (112th), H.R. 3468 (112th), H.R. 1483 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.